

Title (en)
ZOSUQUIDAR, DAUNORUBICIN, AND CYTARABINE FOR THE TREATMENT OF CANCER

Title (de)
ZOSUQUIDAR, DAUNORUBICIN UND CYTARABIN ZUR BEHANDLUNG VON KREBS

Title (fr)
ZOSUQUIDAR, DAUNORUBICINE ET CYTARABINE POUR LE TRAITEMENT DU CANCER

Publication
EP 1898916 A4 20081015 (EN)

Application
EP 06774465 A 20060630

Priority
• US 2006025993 W 20060630
• US 69693005 P 20050706
• US 41683206 A 20060503
• US 41682906 A 20060503
• US 41657106 A 20060503

Abstract (en)
[origin: WO2007008490A2] The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating newly diagnosed Acute Myelogenous Leukemia (AML).

IPC 8 full level
A61K 31/497 (2006.01); **A61K 31/135** (2006.01); **A61K 31/136** (2006.01); **A61K 31/337** (2006.01); **A61K 31/351** (2006.01); **A61K 31/365** (2006.01); **A61K 31/381** (2006.01); **A61K 31/404** (2006.01); **A61K 31/437** (2006.01); **A61K 31/4709** (2006.01); **A61K 31/506** (2006.01); **A61K 31/513** (2006.01); **A61K 31/538** (2006.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01)

CPC (source: EP KR)
A61K 31/136 (2013.01 - EP); **A61K 31/337** (2013.01 - EP KR); **A61K 31/351** (2013.01 - EP); **A61K 31/365** (2013.01 - EP); **A61K 31/381** (2013.01 - EP); **A61K 31/404** (2013.01 - EP); **A61K 31/437** (2013.01 - EP); **A61K 31/4709** (2013.01 - EP KR); **A61K 31/4745** (2013.01 - KR); **A61K 31/506** (2013.01 - EP); **A61K 31/513** (2013.01 - EP); **A61K 31/538** (2013.01 - EP); **A61K 31/704** (2013.01 - KR); **A61K 39/395** (2013.01 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

C-Set (source: EP)
1. **A61K 31/136 + A61K 2300/00**
2. **A61K 31/513 + A61K 2300/00**
3. **A61K 31/538 + A61K 2300/00**
4. **A61K 39/395 + A61K 2300/00**
5. **A61K 31/337 + A61K 2300/00**
6. **A61K 31/351 + A61K 2300/00**
7. **A61K 31/365 + A61K 2300/00**
8. **A61K 31/381 + A61K 2300/00**
9. **A61K 31/404 + A61K 2300/00**
10. **A61K 31/437 + A61K 2300/00**
11. **A61K 31/4709 + A61K 2300/00**
12. **A61K 31/506 + A61K 2300/00**

Citation (search report)
• [X] WO 0205818 A2 20020124 - LILLY CO ELI [US], et al
• [X] GERRARD GARETH ET AL: "Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine", HAEMATOLOGICA, vol. 89, no. 7, July 2004 (2004-07-01), pages 782 - 790, XP002489757, ISSN: 0390-6078
• [X] CRIPE LARRY D ET AL: "A phase II trial of zosuquidar (LY335979), a modulator of P-glycoprotein (PgP) activity, plus daunorubicin and high-dose cytarabine in patients with newly-diagnosed secondary acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-t) or relapsed/refractory AML", BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), & 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 595a, XP008094627, ISSN: 0006-4971
• [X] FRACASSO P M ET AL: "Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies", CLINICAL CANCER RESEARCH 20041101 US, vol. 10, no. 21, 1 November 2004 (2004-11-01), pages 7220 - 7228, XP003005927, ISSN: 1078-0432
• [X] RUBIN E H ET AL: "A Phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies", CLINICAL CANCER RESEARCH 20021201 US, vol. 8, no. 12, 1 December 2002 (2002-12-01), pages 3710 - 3717, XP002489759, ISSN: 1078-0432
• [A] MAHADEVAN D ET AL: "Targeting the multidrug resistance-1 transporter in AML: Molecular regulation and therapeutic strategies", BLOOD 20041001 US, vol. 104, no. 7, 1 October 2004 (2004-10-01), pages 1940 - 1951, XP002489760, ISSN: 0006-4971
• [A] LARSON R A ET AL: "Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002", LEUKEMIA 200312 GB, vol. 17, no. 12, December 2003 (2003-12-01), pages 2358 - 2382, XP002489761, ISSN: 0887-6924
• See references of WO 2007008490A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2007008490 A2 20070118; WO 2007008490 A3 20080110; AU 2006269492 A1 20070118; CA 2614324 A1 20070118; EP 1898916 A2 20080319; EP 1898916 A4 20081015; JP 2009501707 A 20090122; KR 20080034151 A 20080418

DOCDB simple family (application)
US 2006025993 W 20060630; AU 2006269492 A 20060630; CA 2614324 A 20060630; EP 06774465 A 20060630; JP 2008520333 A 20060630; KR 20087003227 A 20080205